Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.
Fiche publication
Date publication
mars 2017
Journal
Medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DELMER Alain
Tous les auteurs :
Quinquenel A, Maestraggi Q, Lecoq-Lafon C, Peffault de Latour R, Delmer A, Servettaz A
Lien Pubmed
Résumé
Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant acquired hematopoietic stem cell disease, which can be revealed by hemolytic anemia, thromboembolism, or bonemarrow failure. Thrombosis can occur at any site, but coronary thrombosis is extremely rare. Controlled trials have demonstrated that eculizimab, an inhibitor of the terminal complement cascade, was able to reduce both hemolysis and thrombosis, but its efficacy in cases of PNH with coronary thrombosis is unknown.
Mots clés
Aged, Antibodies, Monoclonal, Humanized, therapeutic use, Coronary Thrombosis, diagnosis, Coronary Vessels, diagnostic imaging, Delayed Diagnosis, Fatal Outcome, Hemoglobinuria, Paroxysmal, diagnosis, Humans, Immunologic Factors, therapeutic use, Male
Référence
Medicine (Baltimore). 2017 03;96(12):e6403